Nephron Clinical Practice

Original Paper

Does Treatment with Corticosteroids and Cyclosporine Reduce Transglutaminase Type 2 Expression in the Renal Tissue of Patients with Membranous Nephropathy?

Papasotiriou M.a · Kalliakmani P.a · Huang L.b · Gerolymos M.a · Goumenos D.S.a · Johnson T.S.b

Author affiliations

aDepartment of Nephrology and Renal Transplantation, University Hospital of Patras, Patras, Greece; bAcademic Unit of Nephrology, Sheffield Kidney Institute, University of Sheffield, Sheffield, UK

Keywords: CyclosporineInterstitial fibrosisMembranous nephropathyTransglutaminase type 2

Related Articles for ""
Nephron Clin Pract 2012;121:c60–c67
https://doi.org/10.1159/000341116

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 21, 2012
Accepted: June 12, 2012
Published online: October 25, 2012
Issue release date: December 2012

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC

Abstract

Background/Aims: Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults. Transglutaminase type 2 (TG2) contributes to renal scarring through altering extracellular matrix homeostasis. In this study we hypothesized that immunosuppressive treatment would downregulate TG2 expression leading to reduced fibrosis, and subsequently TG2 would have value as a biomarker of progression of MN. Methods: TG2 expression was studied by immunofluorescence in kidney biopsy sections from 32 patients with MN and was compared to control biopsies. All patients were subsequently treated by a combination of cyclosporine and prednisolone for at least 24 months with a repeat biopsy taken in 14 patients. Results: Twenty-two out of 32 patients showed stable renal function, whereas 10 showed doubling of baseline serum creatinine and 5 of them reached end-stage renal disease during the 5-year follow-up. At the end of the follow-up, 22 out of 32 patients were in remission of nephrotic syndrome. TG2 immunostaining was increased in sections from patients with MN compared to healthy controls (p = 0.0002). TG2 at diagnosis was more intense in patients with severer interstitial fibrosis and advanced glomerular sclerosis. TG2 significantly increased in most patients in the repeat biopsies after treatment (p < 0.0001), whereas patients who showed a marked increase in interstitial fibrosis in the repeat biopsy had significantly more TG2 expression in the first biopsy (p = 0.02). Conclusion: TG2 expression is increased in MN patients and continues to increase despite immunosuppressive treatment. However, early detection of TG2 might be of value in MN since increased TG2 production seems to precede extensive interstitial fibrosis.

© 2012 S. Karger AG, Basel



Related Articles:

References

  1. Haas M: Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis 1997;30:621–631.
    External Resources
  2. Maisonneuve P, Agodoa L, Gellert R, et al: Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000;35:157–165.
    External Resources
  3. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11–21.
    External Resources
  4. Cattran DC: Idiopathic membranous glomerulonephritis. Kidney Int 2001;59:1983–1994.
    External Resources
  5. Ponticelli C, Passerini P: Can prognostic factors assist therapeutic decisions in idiopathic membranous nephropathy? J Nephrol 2010;23:156–163.
    External Resources
  6. Nangaku M: Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med 2004;43:9–17.
    External Resources
  7. Shweke N, Boulos N, Jouanneau C, et al: Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol 2008;173:631–642.
    External Resources
  8. Douthwaite JA, Johnson TS, Haylor JL, Watson P, El Nahas AM: Effects of transforming growth factor-beta1 on renal extracellular matrix components and their regulating proteins. J Am Soc Nephrol 1999;10:2109–2119.
    External Resources
  9. Goumenos DS, Tsamandas AC, Oldroyd S, et al: Transforming growth factor-beta(1) and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron 2001;87:240–248.
    External Resources
  10. Griffin M, Casadio R, Bergamini CM: Transglutaminases: nature’s biological glues. Biochem J 2002;368:377–396.
    External Resources
  11. Johnson TS, Griffin M, Thomas GL, et al: The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 1997;99:2950–2960.
    External Resources
  12. Johnson TS, El-Koraie AF, Skill NJ, et al: Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 2003;14:2052–2062.
    External Resources
  13. Fisher M, Jones RA, Huang L, et al: Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. Matrix Biol 2009;28:20–31.
    External Resources
  14. Collighan RJ, Griffin M: Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids 2009;36:659–670.
    External Resources
  15. Nunes I, Gleizes PE, Metz CN, Rifkin DB: Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 1997;136:1151–1163.
    External Resources
  16. Johnson TS, Skill NJ, El Nahas AM, et al: Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am Soc Nephrol 1999;10:2146–2157.
    External Resources
  17. Kalliakmani P, Koutroulia E, Sotsiou F, Vlachojannis JG, Goumenos DS: Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy. Nephrology 2010;15:762–767.
    External Resources
  18. Schwartz MM: Membranous GN. Heptinstall’s Pathology of the Kidney, ed 5. Philadelphia, Lippincott-Raven Publishers, 1998, pp 259–307.
  19. Huang L, Haylor JL, Hau Z, et al: Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int 2009;76:383–394.
    External Resources
  20. Troyanov S, Roasio L, Pandes M, Herzenberg AM, Cattran DC: Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int 2006;69:1641–1648.
    External Resources
  21. Shiiki H, Saito T, Nishitani Y, et al: Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 2004;65:1400–1407.
    External Resources
  22. Goumenos DS, Katopodis KP, Passadakis P, et al: Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Am J Nephrol 2007;27:226–231.
    External Resources
  23. Cattran DC, Appel GB, Hebert LA, et al, North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59:1484–1490.
    External Resources
  24. Cattran DC, Greenwood C, Ritchie S, et al: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995;47:1130–1135.
    External Resources
  25. Goumenos DS, Kalliakmani P, Tsakas S, Sotsiou F, Vlachojannis JG: The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol 2004;61:17–24.
    External Resources
  26. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D: Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006;21:3127–3132.
    External Resources
  27. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD: Mechanism of the antiproteinuric effect of cyclosporin in membranous nephropathy. J Am Soc Nephrol 1996;7:290–298.
    External Resources
  28. Miyamoto Y, Myomoto A, Sakaguchi Y, Yamaguchi-Yamada M, Uchio-Yamda K, Manabe N: Localization of tissue transglutaminase (tTG) in kidney of ICR-derived glomerulonephritis (ICGN) mice. Exp Anim 2009;58:375–382.
    External Resources
  29. Ikee R, Kobayashi S, Hemmi N, et al: Involvement of transglutaminase-2 in pathological changes in renal disease. Nephron Clin Pract 2007;105:139–146.
    External Resources
  30. Roberts IS, Burrows C, Shanks JH, Venning M, McWilliam LJ: Interstitial myofibroblasts: predictors of progression in membranous nephropathy. J Clin Pathol 1997;50:123–127.
    External Resources
  31. Johnson TS, Abo-Zenah H, Skill JN, et al: Tissue transglutaminase: a mediator and predictor of chronic allograft nephropathy? Transplantation 2004;77:1667–1675.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 21, 2012
Accepted: June 12, 2012
Published online: October 25, 2012
Issue release date: December 2012

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 1


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2012, Vol.121, No. 1-2

December 2012

Article

Recommend This
TOP